Close Menu

NEW YORK (GenomeWeb) – NeoGenomics today reported a 25 percent year-over-year jump in its Q4 revenues, buoyed by its recently completed acquisition of Genoptix.

The cancer genetic testing company reported revenues of $76.5 million for the three-month period ended Dec. 31, 2018, up from restated revenues of $61.4 million in the same period last year. The consensus Wall Street estimate was $71.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
17

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.